Al­ler­gan chief snaps up a ri­val biotech for $195M in cash, plus. Deal beefs up the aes­thet­ics pipeline

Just af­ter the start of the year, the crew of ex-Al­ler­gan ex­ecs that launched Bon­ti raised more than $15 mil­lion to back their de­vel­op­ment of a ri­val bot­u­linum neu­ro­tox­in dubbed EB-001 for ther­a­peu­tic and aes­thet­ic us­es.

And Al­ler­gan $AGN wants it.

The bio­phar­ma com­pa­ny has wrapped a deal to buy Bon­ti for $195 mil­lion up­front, mark­ing a nice pay­back for the founders and in­vestors, who had gath­ered a bit more than $36 mil­lion for the ven­ture. There are mile­stones, but no one spelled it out in the re­lease out Fri­day morn­ing.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN